Tag Therapeutics
Milan, IT · 1 known investors
TAG Therapeutics develops TELOBLOCK, an antisense nucleotide therapy that inhibits the DNA damage response at short or damaged telomeres to reduce cellular senescence, targeting telomere biology disorders and age-related diseases such as idiopathic pulmonary fibrosis and bone marrow failure. The company also explores ex-vivo applications to improve immune cell fitness for bone marrow transplantation and cancer immunotherapies.
Founders & leadership
FD
Fabrizio d'Adda di FagagnaScientific Founder
Investors · 1
Frequently asked questions
- What does Tag Therapeutics do?
- TAG Therapeutics develops TELOBLOCK, an antisense nucleotide therapy that inhibits the DNA damage response at short or damaged telomeres to reduce cellular senescence, targeting telomere biology disorders and age-related diseases such as idiopathic pulmonary fibrosis and bone marrow failure. The company also explores ex-vivo applications to improve immune cell fitness for bone marrow transplantation and cancer immunotherapies.
- Who founded Tag Therapeutics?
- Tag Therapeutics was founded by Fabrizio d'Adda di Fagagna.
- Who are Tag Therapeutics's investors?
- Tag Therapeutics's investors include Kinled Holding.
- Where is Tag Therapeutics headquartered?
- Tag Therapeutics is headquartered in Milan, IT.